FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Clin Med / Agmatine Administration Effects on Equine Gastric Ulceration...
Journal of clinical medicine2022; 11(24); doi: 10.3390/jcm11247283

Agmatine Administration Effects on Equine Gastric Ulceration and Lameness.

Abstract: Osteoarthritis (OA) accounts for up to 60% of equine lameness. Agmatine, a decarboxylated arginine, may be a viable option for OA management, based on reports of its analgesic properties. Six adult thoroughbred horses, with lameness attributable to thoracic limb OA, received either daily oral phenylbutazone (6.6 mg/kg), agmatine sulfate (25 mg/kg) or a control for 30 days, with 21-day washout periods between treatments. Subjective lameness, thoracic limb ground reaction forces (GRF), plasma agmatine and agmatine metabolite levels were evaluated using an established rubric, a force platform, and mass spectrometry, respectively, before, during and after each treatment period. Gastric ulceration and plasma chemistries were evaluated before and after treatments. Braking GRFs were greater after 14 and 29 days of agmatine compared to phenylbutazone administration. After 14 days of phenylbutazone administration, vertical GRFs were greater than for agmatine or the control. Glandular mucosal ulcer scores were lower after agmatine than phenylbutazone administration. Agmatine plasma levels peaked between 30 and 60 min and were largely undetectable by 24 h after oral administration. In contrast, plasma citric acid levels increased throughout agmatine administration, representing a shift in the metabolomic profile. Agmatine may be a viable option to improve thoracic limb GRFs while reducing the risk of glandular gastric ulceration in horses with OA.
Get Full Text
Publication Date: 2022-12-08 PubMed ID: 36555900PubMed Central: PMC9780949DOI: 10.3390/jcm11247283Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research examines the effects of agmatine administration on equine lameness due to osteoarthritis and gastric ulceration. It suggests that agmatine could improve lameness and reduce gastric ulceration in horses suffering from osteoarthritis.

Identifying the Research Problem

  • The research primarily tackles the problem of osteoarthritis (OA), a common condition responsible for up to 60% of lameness in horses. The pain and disability from OA cause significant distress to the horse and challenge the care providers.
  • The study proposes to examine the potential of agmatine – a by-product formed when arginine, an amino acid, undergoes the process of decarboxylation – as a possible effective treatment for equine OA. This proposition is based on reports that attribute pain-relieving properties to agmatine.

Research Methodology

  • Six adult thoroughbred horses with OA-related lameness were part of the experiment. Each horse received either a daily dose of phenylbutazone, agmatine sulfate, or a control over 30 days. There were 21-day washout periods between each treatment to eliminate residual effects.
  • The key metrics assessed were subjective lameness, thoracic limb ground reaction forces (GRF), plasma agmatine and agmatine metabolite levels. These were evaluated using a rubric, a force platform, and mass spectrometry, respectively. Assessments took place before, during, and after each treatment cycle.
  • Additionally, the study also monitored gastric ulceration status and plasma chemistry before and after the treatment periods.

Research Findings

  • The results showed an enhancement in the braking ground reaction forces after 14 and 29 days of agmatine administration, compared to phenylbutazone – a non-steroidal anti-inflammatory drug commonly used in horses.
  • After 14 days, the horses treated with phenylbutazone presented higher vertical ground reaction forces than those treated with agmatine or the control.
  • Observations also showed that the horses had lower glandular mucosal ulcer scores (indicating less ulceration) after agmatine treatment compared to phenylbutazone administration.
  • Regarding plasma chemistry, agmatine levels peaked between 30 to 60 minutes but were mostly undetectable after 24 hours of the administration. In contrast, the levels of plasma citric acid, a metabolite, increased during the agmatine treatment, suggesting a shift in metabolomic profile.

Conclusion and Recommendations

  • Given the findings, the research suggests that agmatine could be a potential treatment for improving thoracic limb ground reaction forces in horses, essentially helping manage lameness caused by OA.
  • Moreover, it can do this while also reducing the risk of glandular gastric ulceration, a stated side effect of commonly used medicines like phenylbutazone.

Cite This Article

APA
Taguchi T, Morales Yniguez FJ, Takawira C, Andrews FM, Lopez MJ. (2022). Agmatine Administration Effects on Equine Gastric Ulceration and Lameness. J Clin Med, 11(24). https://doi.org/10.3390/jcm11247283

Publication

Journal of clinical medicine
ISSN: 2077-0383
NlmUniqueID: 101606588
Country: Switzerland
Language: English
Volume: 11
Issue: 24

Researcher Affiliations

Taguchi, Takashi
  • Laboratory for Equine and Comparative Orthopedic Research, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Morales Yniguez, Francisco J
  • Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Takawira, Catherine
  • Laboratory for Equine and Comparative Orthopedic Research, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Andrews, Frank M
  • Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Lopez, Mandi J
  • Laboratory for Equine and Comparative Orthopedic Research, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Grant Funding

  • 1443 / United States Department of Agriculture
  • Equine Health Studies Program / Louisiana State University

Conflict of Interest Statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

This article includes 72 references
  1. Schlueter AE, Orth MW. Equine osteoarthritis: A brief review of the disease and its causes.. Equine Comp. Exerc. Physiol. 2007;1:221–231.
    doi: 10.1079/ECP200428google scholar: lookup
  2. Keegan KG. Evidence-based lameness detection and quantification.. Vet. Clin. N. Am. Equine Pract. 2007;23:403–423.
    doi: 10.1016/j.cveq.2007.04.008pubmed: 17616320google scholar: lookup
  3. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse—A review.. Vet. J. 2006;171:51–69.
    doi: 10.1016/j.tvjl.2004.07.008pubmed: 16427582google scholar: lookup
  4. Nicolás FV, Tomas JV, Marcos F, María FL. Inefficacy of topical diclofenac in arthritic horses.. Am. J. Anim. Vet. Sci. 2006;1:8–12.
    doi: 10.3844/ajavsp.2006.8.12google scholar: lookup
  5. Banse HE, MacLeod H, Crosby C, Windeyer MC. Prevalence of and risk factors for equine glandular and squamous gastric disease in polo horses.. Can. Vet. J. Rev. Vet. Can. 2018;59:880–884.
    pmc: PMC6049336pubmed: 30104780
  6. Tomas A, Marcellin-Little DJ, Roe SC, Motsinger-Reif A, Lascelles BD. Relationship between mechanical thresholds and limb use in dogs with coxofemoral joint oa-associated pain and the modulating effects of pain alleviation from total hip replacement on mechanical thresholds.. Vet. Surg. 2014;43:542–548.
    doi: 10.1111/j.1532-950X.2014.12160.xpubmed: 24512340google scholar: lookup
  7. Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessell I, Tracey I. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients.. Arthritis Rheum. 2009;61:1226–1234.
    doi: 10.1002/art.24837pubmed: 19714588google scholar: lookup
  8. Vo T, Rice ASC, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: How do we explain continued widespread use?. Pain. 2009;143:169–171.
    doi: 10.1016/j.pain.2009.03.013pubmed: 19362418google scholar: lookup
  9. Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. Neuropathic pain in osteoarthritis: A review of pathophysiological mechanisms and implications for treatment.. Semin. Arthritis Rheum. 2014;44:145–154.
    doi: 10.1016/j.semarthrit.2014.05.011pubmed: 24928208google scholar: lookup
  10. Pujol R, Girard CA, Richard H, Hassanpour I, Binette MP, Beauchamp G, McDougall JJ, Laverty S. Synovial nerve fiber density decreases with naturally-occurring osteoarthritis in horses.. Osteoarthr. Cartil. 2018;26:1379–1388.
    doi: 10.1016/j.joca.2018.06.006pubmed: 29958917google scholar: lookup
  11. Jones E, Viñuela-Fernandez I, Eager RA, Delaney A, Anderson H, Patel A, Robertson DC, Allchorne A, Sirinathsinghji EC, Milne EM. Neuropathic changes in equine laminitis pain.. Pain. 2007;132:321–331.
    doi: 10.1016/j.pain.2007.08.035pubmed: 17935886google scholar: lookup
  12. Sluka KA, Willis WD, Westlund KN. Central control of peripheral joint inflammation and heat hyperalgesia.. Prog. Pain Res. Manag. 1994;2:359–371.
    pmc: PMC3953218pubmed: 24634572
  13. Fiorentino PM, Tallents RH, Miller J-NH, Brouxhon SM, O’Banion MK, Puzas JE, Kyrkanides S. Spinal interleukin-1β in a mouse model of arthritis and joint pain.. Arthritis Rheum. 2008;58:3100–3109.
    doi: 10.1002/art.23866pubmed: 18821694google scholar: lookup
  14. Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, Carey Satterfield M, Smith SB, Spencer TE, Yin Y. Arginine metabolism and nutrition in growth, health and disease.. Amino Acids. 2009;37:153–168.
    doi: 10.1007/s00726-008-0210-ypmc: PMC2677116pubmed: 19030957google scholar: lookup
  15. Keynan O, Mirovsky Y, Dekel S, Gilad VH, Gilad GM. Safety and Efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. An open-label, dose-escalating study followed by a randomized, double-blind, placebo-controlled trial.. Pain Med. 2010;11:356–368.
    doi: 10.1111/j.1526-4637.2010.00808.xpubmed: 20447305google scholar: lookup
  16. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Pt 1. Biochem. J. 1996;316:247–249.
    doi: 10.1042/bj3160247pmc: PMC1217329pubmed: 8645212google scholar: lookup
  17. Pinthong D, Wright IK, Hanmer C, Millns P, Mason R, Kendall DA, Wilson VG. Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors.. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1995;351:10–16.
    doi: 10.1007/BF00169058pubmed: 7715734google scholar: lookup
  18. Raasch W, Schafer U, Chun J, Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.. Br. J. Pharmacol. 2001;133:755–780.
    doi: 10.1038/sj.bjp.0704153pmc: PMC1572857pubmed: 11454649google scholar: lookup
  19. Roerig SC. Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception.. Ann. N. Y. Acad. Sci. 2003;1009:116–126.
    doi: 10.1196/annals.1304.011pubmed: 15028575google scholar: lookup
  20. Piletz JE, Aricioglu F, Cheng JT, Fairbanks CA, Gilad VH, Haenisch B, Halaris A, Hong S, Lee JE, Li J. Agmatine: Clinical applications after 100 years in translation.. Drug Discov. Today. 2013;18:880–893.
    doi: 10.1016/j.drudis.2013.05.017pubmed: 23769988google scholar: lookup
  21. Zhu MY, Wang WP, Huang J, Feng YZ, Regunathan S, Bissette G. Repeated immobilization stress alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels.. Neurochem. Int. 2008;53:346–354.
    doi: 10.1016/j.neuint.2008.09.001pmc: PMC2654250pubmed: 18832001google scholar: lookup
  22. Gilad GM, Gilad VH. Brain polyamine stress response: Recurrence after repetitive stressor and inhibition by lithium.. J. Neurochem. 1996;67:1992–1996.
    doi: 10.1046/j.1471-4159.1996.67051992.xpubmed: 8863505google scholar: lookup
  23. Aricioglu F, Paul IA, Regunathan S. Agmatine reduces only peripheral-related behavioral signs, not the central signs, of morphine withdrawal in nNOS deficient transgenic mice.. Neurosci. Lett. 2004;354:153–157.
    doi: 10.1016/j.neulet.2003.10.010pubmed: 14698461google scholar: lookup
  24. Onal A, Delen Y, Ulker S, Soykan N. Agmatine attenuates neuropathic pain in rats: Possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum.. Life Sci. 2003;73:413–428.
    doi: 10.1016/S0024-3205(03)00297-2pubmed: 12759136google scholar: lookup
  25. Satriano J, Schwartz D, Ishizuka S, Lortie MJ, Thomson SC, Gabbai F, Kelly CJ, Blantz RC. Suppression of inducible nitric oxide generation by agmatine aldehyde: Beneficial effects in sepsis.. J. Cell. Physiol. 2001;188:313–320.
    doi: 10.1002/jcp.1119pubmed: 11473357google scholar: lookup
  26. Karadag HC, Ulugol A, Tamer M, Ipci Y, Dokmeci I. Systemic agmatine attenuates tactile allodynia in two experimental neuropathic pain models in rats.. Neurosci. Lett. 2003;339:88–90.
    doi: 10.1016/S0304-3940(02)01456-8pubmed: 12618307google scholar: lookup
  27. Taguchi T, Koh R, Takawira C, Rademacher N, Gilad GM, Aronson RD, Lopez MJ. Agmatine for pain management in dogs with coxofemoral joint osteoarthritis: A pilot study.. Front. Vet. Sci. 2018;5:311.
    doi: 10.3389/fvets.2018.00311pmc: PMC6315183pubmed: 30631768google scholar: lookup
  28. Pelletier J-P, Martel-Pelletier J. The Novartis-ILAR rheumatology prize 2001 osteoarthritis: From molecule to man.. Arthritis Res. 2002;4:13–19.
    doi: 10.1186/ar378pmc: PMC128913pubmed: 11879533google scholar: lookup
  29. Tung JT, Venta PJ, Caron JP. Inducible nitric oxide expression in equine articular chondrocytes: Effects of antiinflammatory compounds.. Osteoarthr. Cartil. 2002;10:5–12.
    doi: 10.1053/joca.2001.0476pubmed: 11795978google scholar: lookup
  30. Al Masri AA, El Eter E. Agmatine induces gastric protection against ischemic injury by reducing vascular permeability in rats.. World J. Gastroenterol. 2012;18:2188–2196.
    doi: 10.3748/wjg.v18.i18.2188pmc: PMC3351768pubmed: 22611311google scholar: lookup
  31. Zádori ZS, Tóth VE, Fehér Á, Philipp K, Németh J, Gyires K. Evidence for the gastric cytoprotective effect of centrally injected agmatine.. Brain Res. Bull. 2014;108:51–59.
    doi: 10.1016/j.brainresbull.2014.07.008pubmed: 25171957google scholar: lookup
  32. Kitada Y, Muramatsu K, Toju H, Kibe R, Benno Y, Kurihara S, Matsumoto M. Bioactive polyamine production by a novel hybrid system comprising multiple indigenous gut bacterial strategies.. Sci. Adv. 2018;4:eaat0062.
    doi: 10.1126/sciadv.aat0062pmc: PMC6021145pubmed: 29963630google scholar: lookup
  33. Brzozowski T, Drozdowicz D, Maka J, Polonczyk-Pytko J, Konturek SJ. Role of polyamines in gastroprotection induced by epidermal growth factor.. J. Physiol. Pharm. 1991;42:181–193.
    pubmed: 1782416
  34. Ma L, Wang WP, Chow JYC, Lam SK, Cho CH. The role of polyamines in gastric mucus synthesis inhibited by cigarette smoke or its extract.. Gut. 2000;47:170–177.
    doi: 10.1136/gut.47.2.170pmc: PMC1728002pubmed: 10896906google scholar: lookup
  35. . LAMENESS EXAMS: Evaluating the Lame Horse.. [(accessed on 9 November 2022)].
  36. Keegan KG, Dent EV, Wilson DA, Janicek J, Kramer J, Lacarrubba A, Walsh DM, Cassells MW, Esther TM, Schiltz P. Repeatability of subjective evaluation of lameness in horses.. Equine Vet. J. 2010;42:92–97.
    doi: 10.2746/042516409X479568pubmed: 20156242google scholar: lookup
  37. Mirza MH, Bommala P, Richbourg HA, Rademacher N, Kearney MT, Lopez MJ. Gait changes vary among horses with naturally occurring osteoarthritis following intra-articular administration of autologous platelet-rich plasma.. Front. Vet. Sci. 2016;3:29.
    doi: 10.3389/fvets.2016.00029pmc: PMC4829588pubmed: 27148544google scholar: lookup
  38. Lopez MJ, Quinn MM, Markel MD. Evaluation of gait kinetics in puppies with coxofemoral joint laxity.. Am. J. Vet. Res. 2006;67:236–241.
    doi: 10.2460/ajvr.67.2.236pmc: PMC2094731pubmed: 16454627google scholar: lookup
  39. Council TEGU. Recommendations for the diagnosis and treatment of equine gastric ulcer syndrome (EGUS): The equine gastric ulcer council.. Equine Vet. Educ. 1999;11:262–272.
    doi: 10.1111/j.2042-3292.1999.tb00961.xgoogle scholar: lookup
  40. MacAllister CG, Andrews FM, Deegan E, Ruoff W, Olovson SG. A scoring system for gastric ulcers in the horse.. Equine Vet. J. 1997;29:430–433.
    doi: 10.1111/j.2042-3306.1997.tb03154.xpubmed: 9413714google scholar: lookup
  41. Bialer M, Sussan S, Abu Salach O, Danenberg HD, Ben-David J, Gibor Y, Laor A. Criteria to assess in vivo performance of sustained release products: Application to diltiazem formulations.. J. Pharm. Sci. 1995;84:1160–1163.
    doi: 10.1002/jps.2600841005pubmed: 8801328google scholar: lookup
  42. Rojas DR, Kuner R, Agarwal N. Metabolomic signature of type 1 diabetes-induced sensory loss and nerve damage in diabetic neuropathy.. J. Mol. Med. 2019;97:845–854.
    doi: 10.1007/s00109-019-01781-1pubmed: 30949723google scholar: lookup
  43. Abdel-Salam OM, Youness ER, Mohammed NA, Morsy SM, Omara EA, Sleem AA. Citric acid effects on brain and liver oxidative stress in lipopolysaccharide-treated mice.. J. Med. Food. 2014;17:588–598.
    doi: 10.1089/jmf.2013.0065pmc: PMC4026104pubmed: 24433072google scholar: lookup
  44. Doucet MY, Bertone AL, Hendrickson D, Hughes F, Macallister C, McClure S, Reinemeyer C, Rossier Y, Sifferman R, Vrins AA. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.. J. Am. Vet. Med. Assoc. 2008;232:91–97.
    doi: 10.2460/javma.232.1.91pubmed: 18167116google scholar: lookup
  45. Whitfield-Cargile CM, Coleman MC, Cohen ND, Chamoun-Emanuelli AM, DeSolis CN, Tetrault T, Sowinski R, Bradbery A, Much M. Effects of phenylbutazone alone or in combination with a nutritional therapeutic on gastric ulcers, intestinal permeability, and fecal microbiota in horses.. J. Vet. Intern. Med. Am. Coll. Vet. Intern. Med. 2021;35:1121–1130.
    doi: 10.1111/jvim.16093pmc: PMC7995434pubmed: 33656183google scholar: lookup
  46. Beluche LA, Bertone AL, Anderson DE, Rohde C. Effects of oral administration of phenylbutazone to horses on in vitro articular cartilage metabolism.. Am. J. Vet. Res. 2001;62:1916–1921.
    doi: 10.2460/ajvr.2001.62.1916pubmed: 11763181google scholar: lookup
  47. Soma LR, Uboh CE, Maylin GM. The use of phenylbutazone in the horse.. J. Vet. Pharmacol. Ther. 2012;35:1–12.
    doi: 10.1111/j.1365-2885.2011.01299.xpubmed: 21668837google scholar: lookup
  48. Pirkulashvili N, Tsiklauri N, Nebieridze M, Tsagareli MG. Antinociceptive tolerance to NSAIDs in the agranular insular cortex is mediated by opioid mechanism.. J. Pain Res. 2017;10:1561–1568.
    doi: 10.2147/JPR.S138360pmc: PMC5505549pubmed: 28740423google scholar: lookup
  49. Osani MC, Vaysbrot EE, Zhou M, McAlindon TE, Bannuru RR. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: A systematic review and meta-analysis.. Arthritis Care Res. 2020;72:641–651.
    doi: 10.1002/acr.23884pmc: PMC6761047pubmed: 30908885google scholar: lookup
  50. Lees P, Toutain PL. Pharmacokinetics, pharmacodynamics, metabolism, toxicology and residues of phenylbutazone in humans and horses.. Vet. J. 2013;196:294–303.
    doi: 10.1016/j.tvjl.2013.04.019pubmed: 23721873google scholar: lookup
  51. Lee DV, Stakebake EF, Walter RM, Carrier DR. Effects of mass distribution on the mechanics of level trotting in dogs.. J. Exp. Biol. 2004;207:1715–1728.
    doi: 10.1242/jeb.00947pubmed: 15073204google scholar: lookup
  52. Granatosky MC, Fitzsimons A, Zeininger A, Schmitt D. Mechanisms for the functional differentiation of the propulsive and braking roles of the forelimbs and hindlimbs during quadrupedal walking in primates and felines.. J. Exp. Biol. 2018;221:jeb162917.
    doi: 10.1242/jeb.162917pubmed: 29170258google scholar: lookup
  53. Waldern NM, Wiestner T, von Peinen K, Gómez Alvarez CG, Roepstorff L, Johnston C, Meyer H, Weishaupt MA. Influence of different head-neck positions on vertical ground reaction forces, linear and time parameters in the unridden horse walking and trotting on a treadmill.. Equine Vet. J. 2009;41:268–273.
    doi: 10.2746/042516409X397389pubmed: 19469234google scholar: lookup
  54. Rosenberg ML, Tohidi V, Sherwood K, Gayen S, Medel R, Gilad GM. Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study.. Nutrients. 2020;12:576.
    doi: 10.3390/nሂ0576pmc: PMC7071502pubmed: 32102167google scholar: lookup
  55. Pedersen SK, Cribb AE, Read EK, French D, Banse HE. Phenylbutazone induces equine glandular gastric disease without decreasing prostaglandin E(2) concentrations.. J. Vet. Pharmacol. Ther. 2018;41:239–245.
    doi: 10.1111/jvp.12464pubmed: 29148168google scholar: lookup
  56. Banse HE, Andrews FM. Equine glandular gastric disease: Prevalence, impact and management strategies.. Vet. Med. 2019;10:69–76.
    doi: 10.2147/VMRR.S174427pmc: PMC6642651pubmed: 31406687google scholar: lookup
  57. Murray MJ, Eichorn ES. Effects of intermittent feed deprivation, intermittent feed deprivation with ranitidine administration, and stall confinement with ad libitum access to hay on gastric ulceration in horses.. Am. J. Vet. Res. 1996;57:1599–1603.
    pubmed: 8915437
  58. Cole AS, Eastoe JE. Chapter 35-Plaque Metabolism and Dental Disease.. In: Cole A.S., Eastoe J.E., editors. Biochemistry and Oral Biology. 2nd ed. Butterworth-Heinemann; Oxford, UK: 1988. pp. 502–519..
  59. Bergin DH, Jing Y, Williams G, Mockett BG, Zhang H, Abraham WC, Liu P. Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate.. Sci. Rep. 2019;9:12669.
    doi: 10.1038/s41598-019-49078-0pmc: PMC6722093pubmed: 31481723google scholar: lookup
  60. Zain-Hamid R, Ismail Z, Mahendra Raj S, Shuaib IL, Mohsin SSJ. The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients.. Malays. J. Med. Sci. 2002;9:16–20.
    pmc: PMC3436100pubmed: 22969313
  61. Liu Y, Siard M, Adams A, Keowen ML, Miller TK, Garza F Jr, Andrews FM, Seeram NP. Simultaneous quantification of free curcuminoids and their metabolites in equine plasma by LC-ESI-MS/MS.. J. Pharm. Biomed. Anal. 2018;154:31–39.
    doi: 10.1016/j.jpba.2018.03.014pubmed: 29529492google scholar: lookup
  62. Nissim I, Horyn O, Daikhin Y, Chen P, Li C, Wehrli SL, Nissim I, Yudkoff M. The molecular and metabolic influence of long term agmatine consumption.. J. Biol. Chem. 2014;289:9710–9729.
    doi: 10.1074/jbc.M113.544726pmc: PMC3975019pubmed: 24523404google scholar: lookup
  63. Pryor R, Norvaisas P, Marinos G, Best L, Thingholm LB, Quintaneiro LM, De Haes W, Esser D, Waschina S, Lujan C. Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy.. Cell. 2019;178:1299–1312.e1229.
    doi: 10.1016/j.cell.2019.08.003pmc: PMC6736778pubmed: 31474368google scholar: lookup
  64. Wang Y, Hussain SM, Wluka AE, Lim YZ, Abram F, Pelletier JP, Martel-Pelletier J, Cicuttini FM. Association between metformin use and disease progression in obese people with knee osteoarthritis: Data from the osteoarthritis initiative-a prospective cohort study.. Arthritis Res. Ther. 2019;21:127.
    doi: 10.1186/s13075-019-1915-xpmc: PMC6534888pubmed: 31126352google scholar: lookup
  65. Lu CH, Chung CH, Lee CH, Hsieh CH, Hung YJ, Lin FH, Tsao CH, Hsieh PS, Chien WC. Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.. PLoS ONE. 2018;13:e0191242.
    doi: 10.1371/journal.pone.0191242pmc: PMC5791980pubmed: 29385156google scholar: lookup
  66. Dioguardi FS. To Give or not to give? Lessons from the arginine paradox.. Lifestyle Genom. 2011;4:90–98.
    doi: 10.1159/000327777pubmed: 21625171google scholar: lookup
  67. Zhang W, Sun G, Likhodii S, Liu M, Aref-Eshghi E, Harper PE, Martin G, Furey A, Green R, Randell E. Metabolomic analysis of human plasma reveals that arginine is depleted in knee osteoarthritis patients.. Osteoarthr. Cartil. 2016;24:827–834.
    doi: 10.1016/j.joca.2015.12.004pubmed: 26708258google scholar: lookup
  68. Schoonover MJ, Jann HW, Blaik MA. Quantitative comparison of three commonly used treatments for navicular syndrome in horses.. Am. J. Vet. Res. 2005;66:1247–1251.
    doi: 10.2460/ajvr.2005.66.1247pubmed: 16111165google scholar: lookup
  69. Erkert RS, MacAllister CG, Payton ME, Clarke CR. Use of force plate analysis to compare the analgesic effects of intravenous administration of phenylbutazone and flunixin meglumine in horses with navicular syndrome.. Am. J. Vet. Res. 2005;66:284–288.
    doi: 10.2460/ajvr.2005.66.284pubmed: 15757129google scholar: lookup
  70. Ishihara A, Bertone AL, Rajala-Schultz PJ. Association between subjective lameness grade and kinetic gait parameters in horses with experimentally induced forelimb lameness.. Am. J. Vet. Res. 2005;66:1805–1815.
    doi: 10.2460/ajvr.2005.66.1805pubmed: 16273915google scholar: lookup
  71. Burkett BN, Thomason JM, Hurdle HM, Wills RW, Fontenot RL. Effects of Firocoxib, Flunixin Meglumine, and Phenylbutazone on Platelet Function and Thromboxane Synthesis in Healthy Horses.. Vet. Surg. 2016;45:1087–1094.
    doi: 10.1111/vsu.12567pubmed: 27731498google scholar: lookup
  72. Kruger K, Stegmann GF, Becker PJ. Preliminary investigation of concurrent administration of phenylbutazone and romifidine in healthy horses.. Vet. Anaesth. Analg. 2011;38:505–509.
    doi: 10.1111/j.1467-2995.2011.00642.xpubmed: 21831057google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.